الصفحة الرئيسية>>Signaling Pathways>> Neuroscience>> Ophthalmology>>Risuteganib (trifluoroacetate salt)

Risuteganib (trifluoroacetate salt) (Synonyms: ALG-1001)

رقم الكتالوجGC48401

An anti-integrin peptide

Products are for research use only. Not for human use. We do not sell to patients.

Risuteganib (trifluoroacetate salt) التركيب الكيميائي

الحجم السعر المخزون الكميّة
1mg
111٫00
متوفر
5mg
418٫00
متوفر
10mg
780٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Risuteganib is an anti-integrin peptide and a derivative of RGD peptide .1 Risuteganib (400 µM) protects against hydroquinone-induced necrosis and apoptosis, as well as inhibits hydroquinone-induced production of reactive oxygen species (ROS), in human retinal pigment epithelial (RPE) cells.2 It decreases the expression of BAX, VEGFA, and ITB1 in human age-related macular degeneration (AMD) cybrid cell lines when used at a concentration of 20 mg/ml.3 Risuteganib arrests aberrant blood vessel growth mediated by αVβ3, αVβ5, and α5β1 integrins in vivo.1

1.Kaiser, P., Boyer, D.D., Campochiaro, P.A., et al.Integrin peptide therapy: The first wet AMD experienceInvest. Opth. Vis. Sci.54(15)2177(2013) 2.Yang, P., Shao, Z., Besley, N.A., et al.Risuteganib protects against hydroquinone-induced injury in human RPE cellsInvest. Ophthalmol. Vis. Sci.61(10)35(2020) 3.Differential effects of risuteganib and bevacizumab on AMD cybrid cellsExp. Eye Res.203108287(2021)

مراجعات

Review for Risuteganib (trifluoroacetate salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 40 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Risuteganib (trifluoroacetate salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.